Reviewing the Options for Local Estrogen Treatment of Vaginal Atrophy

Overview

Journal Int J Womens Health

Publisher Dove Medical Press

Specialty Gynecology & Obstetrics

Date 2014 Mar 21

PMID 24648775

Citations 10

Authors

Sarah H Lindahl

Affiliations

Soon will be listed here.

Abstract

Background: Vaginal atrophy is a chronic condition with symptoms that include vaginal dryness, pain during sex, itching, irritation, burning, and discharge, as well as various urinary problems. Up to 45% of postmenopausal women may be affected, but it often remains underreported and undertreated. This article aims to review the current recommendations for treatment of vaginal atrophy, and current data on the effectiveness and safety of local vaginal estrogen therapies.

Methods: Literature regarding vaginal atrophy (2007-2012) was retrieved from PubMed and summarized, with emphasis on data related to the treatment of vaginal atrophy with local vaginal estrogen therapy.

Results: Published data support the effectiveness and endometrial safety of low-dose local estrogen therapies. These results further support the general recommendation by the North American Menopause Society that a progestogen is not needed for endometrial protection in patients using low-dose local vaginal estrogen. Benefits of long-term therapy for vaginal atrophy include sustained relief of symptoms as well as physiological improvements (eg, decreased vaginal pH and increased blood flow, epithelial thickness, secretions).

Conclusion: Currently available local vaginal estrogen therapies are well tolerated and effective in relieving symptoms of vaginal atrophy. Recent data support the endometrial safety of low-dose regimens for up to 1 year.

Citing Articles

TSST-1 promotes colonization of within the vaginal tract by activation of CD8 T cells.

Dufresne K, Al K, Craig H, Coleman C, Kasper K, Burton J Infect Immun. 2025; 93(2):e0043924.

PMID: 39840991 PMC: 11834441. DOI: 10.1128/iai.00439-24.

Analysis of factors affecting the accuracy of colposcopic diagnosis of cervical lesions: a retrospective cohort study.

Chu Y, Chen Q, Liu R, Zhou X, Bao M, Wang H Front Med (Lausanne). 2024; 11:1462079.

PMID: 39478822 PMC: 11521855. DOI: 10.3389/fmed.2024.1462079.

Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women.

Taithongchai A, Johnson E, Ismail S, Barron-Millar E, Kernohan A, Thakar R Cochrane Database Syst Rev. 2023; 7:CD014592.

PMID: 37431855 PMC: 10335326. DOI: 10.1002/14651858.CD014592.pub2.

Development of Hormonal Intravaginal Rings: Technology and Challenges.

Rafiei F, Tabesh H, Farzad S, Farzaneh F, Rezaei M, Hosseinzade F Geburtshilfe Frauenheilkd. 2021; 81(7):789-806.

PMID: 34276064 PMC: 8277443. DOI: 10.1055/a-1369-9395.

Vaginal dryness: individualised patient profiles, risks and mitigating measures.

Goncharenko V, Bubnov R, Polivka Jr J, Zubor P, Biringer K, Bielik T EPMA J. 2019; 10(1):73-79.

PMID: 30984316 PMC: 6459457. DOI: 10.1007/s13167-019-00164-3.

References

Mac Bride M, Rhodes D, Shuster L . Vulvovaginal atrophy. Mayo Clin Proc. 2010; 85(1):87-94. PMC: 2800285. DOI: 10.4065/mcp.2009.0413. View

Canonico M, Plu-Bureau G, Lowe G, Scarabin P . Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008; 336(7655):1227-31. PMC: 2405857. DOI: 10.1136/bmj.39555.441944.BE. View

Eugster-Hausmann M, Waitzinger J, Lehnick D . Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets. Climacteric. 2010; 13(3):219-27. DOI: 10.3109/13697137.2010.483297. View

Ulrich L, Naessen T, Elia D, Goldstein J, Eugster-Hausmann M . Endometrial safety of ultra-low-dose Vagifem 10 microg in postmenopausal women with vaginal atrophy. Climacteric. 2010; 13(3):228-37. DOI: 10.3109/13697137.2010.481058. View

Nappi R, Kokot-Kierepa M . Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey. Climacteric. 2011; 15(1):36-44. DOI: 10.3109/13697137.2011.647840. View

Dorr M, Nelson A, Mayer P, Ranganath R, Norris P, Helzner E . Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis. Fertil Steril. 2010; 94(6):2365-8. DOI: 10.1016/j.fertnstert.2010.03.076. View

Stika C . Atrophic vaginitis. Dermatol Ther. 2010; 23(5):514-22. DOI: 10.1111/j.1529-8019.2010.01354.x. View

NACHTIGALL L . Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril. 1994; 61(1):178-80. DOI: 10.1016/s0015-0282(16)56474-7. View

Margolis K, Bonds D, Rodabough R, Tinker L, Phillips L, Allen C . Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004; 47(7):1175-1187. DOI: 10.1007/s00125-004-1448-x. View

10.

Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I . A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol. 1996; 174(1 Pt 1):85-92. DOI: 10.1016/s0002-9378(96)70378-2. View

11.

. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013; 20(9):888-902. DOI: 10.1097/GME.0b013e3182a122c2. View

12.

Nappi R, Kokot-Kierepa M . Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010; 67(3):233-8. DOI: 10.1016/j.maturitas.2010.08.001. View

13.

Scarabin P, Oger E, Plu-Bureau G . Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003; 362(9382):428-32. DOI: 10.1016/S0140-6736(03)14066-4. View

14.

Krychman M . Vaginal estrogens for the treatment of dyspareunia. J Sex Med. 2010; 8(3):666-74. DOI: 10.1111/j.1743-6109.2010.02114.x. View

15.

Simon J, Nachtigall L, Ulrich L, Eugster-Hausmann M, Gut R . Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol. 2010; 116(4):876-883. DOI: 10.1097/AOG.0b013e3181f386bb. View

16.

Santoro N, Komi J . Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009; 6(8):2133-42. DOI: 10.1111/j.1743-6109.2009.01335.x. View

17.

Bachmann G, Bouchard C, Hoppe D, Ranganath R, Altomare C, Vieweg A . Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause. 2009; 16(4):719-27. DOI: 10.1097/gme.0b013e3181a48c4e. View

18.

Robinson D, Cardozo L . Estrogens and the lower urinary tract. Neurourol Urodyn. 2011; 30(5):754-7. DOI: 10.1002/nau.21106. View

19.

Birkhauser M, Panay N, Archer D, Barlow D, Burger H, Gambacciani M . Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric. 2008; 11(2):108-23. DOI: 10.1080/13697130801983921. View

20.

Lokkegaard E, Andreasen A, Jacobsen R, Nielsen L, Agger C, Lidegaard O . Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J. 2008; 29(21):2660-8. DOI: 10.1093/eurheartj/ehn408. View